M&A Deal Summary

Genesis Biotechnology Group Acquires STATKING Clinical Services

On January 6, 2021, Genesis Biotechnology Group acquired life science company STATKING Clinical Services

Acquisition Highlights
  • This is Genesis Biotechnology Group’s 3rd transaction in the Life Science sector.
  • This is Genesis Biotechnology Group’s 4th transaction in the United States.
  • This is Genesis Biotechnology Group’s 1st transaction in Ohio.

M&A Deal Summary
Date 2021-01-06
Target STATKING Clinical Services
Sector Life Science
Buyer(s) Genesis Biotechnology Group
Deal Type Add-on Acquisition

Target

STATKING Clinical Services

Fairfield, Ohio, United States
STATKING Clinical Services provides clinical trial services, including clinical trial management, protocol development, biostatistics, clinical data management, clinical study monitoring, medical writing, medical monitoring, safety reporting, and project management for the regulatory approval of novel drug and medical device products. STATKING Clinical Services was founded in 1989 and is based in Fairfield, Ohio.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genesis Biotechnology Group

Hamilton, New Jersey, United States
Category Company
Sector Life Science
DESCRIPTION

Genesis Biotechnology Group is a consortium of vertically integrated corporate research entities, which facilitates the overall market implementation and delivery of biomedical science products and services related to diagnostics and drug discovery.

DEAL STATS #
Overall 4 of 5
Sector (Life Science) 3 of 4
Type (Add-on Acquisition) 4 of 5
State (Ohio) 1 of 1
Country (United States) 4 of 5
Year (2021) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-05 Comparative Biosciences

Sunnyvale, California, United States

Comparative Biosciences, Inc. is specialized in GLP (Good Laboratory Practice) Toxicology and Safety Pharmacology projects for IND-enabling research studies. This portfolio addition will enable GD3 to expand its pre-clinical services to GLP based studies by (1) offering integrated, single-point-of-contact services throughout the project lifetime, (2) streamlining all phases of the discovery cycle and (3) enabling new discoveries to progress rapidly from project inception through pre-clinical development. Comparative Biosciences was founded in 1996 and is based in Sunnyvale, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-10-07 BioBlocks

San Diego, California, United States

BioBlocks is a collaborative medicinal chemistry research organization that focuses on drug discovery from initial hit through identification of development candidates. The company provides expertise and joins forces with clients to discover compounds qualified for advancement to phase two clinical trials. Aided by a results-based lead optimization model, BioBlocks scientists have developed multiple preclinical candidates for its partners. Its Leap-to-Lead platform provides an alternative source for high-quality tractable leads with multiple possible optimization pathways. BioBlocks was formed in 2002 and is based in San Diego, California.

Buy -
Mergr

Product

Company

Legal